A new analysis of Kite Pharma’s Yescarta (axi-cel) clinical trial patients linked genetic mutations to toxicity risk in CAR-T therapy and identified STXBP2 as a standout signal, with results published in Science Immunology. The study, led by Mark Leick, M.D., at Massachusetts General Hospital, examined Zuma-1 and Zuma-7 data to correlate inherited genetic features with severe adverse events. Leick and colleagues reported that six Zuma-1 patients carrying STXBP2 mutations with loss of function experienced treatment toxicity, while the same relationship did not appear in Zuma-7. The work suggests an inherited predisposition to cytokine-release-syndrome-like toxicity patterns that could inform future CAR-T cell design and patient risk stratification. The research also highlighted a gene tied to the ability of CAR-T cells to replicate in the body, a mechanism that the team is now exploring further. In practical terms, the findings point toward engineering strategies aimed at safer CAR-T profiles without abandoning efficacy—an area of intense focus as more patients seek solid-tumor and earlier-line cellular therapies.